{"log_id": 674509507251596831, "direction": 0, "words_result_num": 42, "words_result": [{"probability": {"variance": 0.000132, "average": 0.997114, "min": 0.929779}, "location": {"width": 864, "top": 123, "height": 41, "left": 170}, "words": "出血:不明原因的红细胞容积、血红蛋白或血压下降提示可能有出血,如果出现出"}, {"probability": {"variance": 2e-06, "average": 0.999034, "min": 0.993649}, "location": {"width": 894, "top": 161, "height": 40, "left": 124}, "words": "血或怀疑出血应停止给药。目前尚没有比伐芦定解毒药物,但其作用会很快消失(T"}, {"probability": {"variance": 0.000697, "average": 0.960478, "min": 0.934085}, "location": {"width": 17, "top": 172, "height": 20, "left": 1017}, "words": "/2"}, {"probability": {"variance": 0.000452, "average": 0.983289, "min": 0.942836}, "location": {"width": 139, "top": 206, "height": 27, "left": 127}, "words": "为35-40min)"}, {"probability": {"variance": 1e-06, "average": 0.999511, "min": 0.995336}, "location": {"width": 865, "top": 232, "height": 42, "left": 172}, "words": "过敏:病人若患有荨麻疹、全身性荨麻疹、胸闷、气喘、低血压和过敏反应需提前"}, {"probability": {"variance": 2e-05, "average": 0.997866, "min": 0.978662}, "location": {"width": 913, "top": 269, "height": 40, "left": 124}, "words": "告知,在休克情况下,利用目前的救治方法治疗。上市后对过敏及过敏致死的临床报道"}, {"probability": {"variance": 1e-05, "average": 0.998513, "min": 0.981971}, "location": {"width": 912, "top": 305, "height": 41, "left": 127}, "words": "非常少(见不良反应)。对以前曾用比伐芦定治疗,已产生抗体的病人要引起注意。接"}, {"probability": {"variance": 3e-06, "average": 0.999133, "min": 0.990613}, "location": {"width": 890, "top": 342, "height": 41, "left": 127}, "words": "受γ射线近距离治疗的患者使用比伐芦定时有增加血栓形成的风险,甚至会导致死亡"}, {"probability": {"variance": 2e-06, "average": 0.999113, "min": 0.99508}, "location": {"width": 279, "top": 386, "height": 28, "left": 134}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0, "average": 0.999774, "min": 0.999589}, "location": {"width": 46, "top": 424, "height": 24, "left": 176}, "words": "孕妇"}, {"probability": {"variance": 2.1e-05, "average": 0.998465, "min": 0.977558}, "location": {"width": 865, "top": 450, "height": 36, "left": 175}, "words": "比伐芦定与阿司匹林合用,由于可能引起新生儿和产妇出血的不良反应,特别是在"}, {"probability": {"variance": 1e-06, "average": 0.999048, "min": 0.994161}, "location": {"width": 799, "top": 485, "height": 38, "left": 127}, "words": "妊娠的最后3个月内,除非必要,不要给孕妇同时使用比伐芦定和阿司匹林"}, {"probability": {"variance": 0, "average": 0.9992, "min": 0.998958}, "location": {"width": 51, "top": 529, "height": 25, "left": 176}, "words": "妊娠"}, {"probability": {"variance": 4e-06, "average": 0.999051, "min": 0.990402}, "location": {"width": 866, "top": 556, "height": 37, "left": 176}, "words": "尽管致畸研究未发现对受孕和胚胎有损害,但动物生殖研究并不一定能预测出药物"}, {"probability": {"variance": 1e-06, "average": 0.99944, "min": 0.994285}, "location": {"width": 913, "top": 593, "height": 37, "left": 128}, "words": "在人体中的反应。由于孕期妇女尚未进行足够的、有良好对照的临床研究,因此除非特"}, {"probability": {"variance": 6e-06, "average": 0.998887, "min": 0.989626}, "location": {"width": 389, "top": 632, "height": 36, "left": 129}, "words": "别需要,孕妇一般不宜使用比伐芦定"}, {"probability": {"variance": 0, "average": 0.999518, "min": 0.998753}, "location": {"width": 74, "top": 672, "height": 28, "left": 177}, "words": "哺乳期"}, {"probability": {"variance": 0, "average": 0.999432, "min": 0.997654}, "location": {"width": 865, "top": 699, "height": 40, "left": 178}, "words": "尚不清楚比伐芦定是否能经人乳分泌,由于许多药物都能经人乳分泌,因此比伐芦"}, {"probability": {"variance": 5e-05, "average": 0.997639, "min": 0.971254}, "location": {"width": 365, "top": 743, "height": 29, "left": 131}, "words": "定用于哺乳期妇女时必须特别注意"}, {"probability": {"variance": 0, "average": 0.999332, "min": 0.998464}, "location": {"width": 129, "top": 779, "height": 28, "left": 140}, "words": "【儿童用药】"}, {"probability": {"variance": 0.00101, "average": 0.992554, "min": 0.840221}, "location": {"width": 584, "top": 809, "height": 35, "left": 177}, "words": "比伐芦定在儿科中使用的安全性和有效性尚未进行评价"}, {"probability": {"variance": 1e-06, "average": 0.999063, "min": 0.997337}, "location": {"width": 131, "top": 849, "height": 28, "left": 140}, "words": "【老年用药】"}, {"probability": {"variance": 0.00694, "average": 0.982228, "min": 0.466313}, "location": {"width": 841, "top": 879, "height": 37, "left": 180}, "words": "比伐芦定用于行PCI的临床试验中,44%患者的年龄265岁,12%的患者>75岁"}, {"probability": {"variance": 3e-06, "average": 0.998872, "min": 0.992897}, "location": {"width": 912, "top": 914, "height": 41, "left": 133}, "words": "年龄大的患者出现出血现象要比年龄小的多,与肝素相比,使用比伐芦定患者的出血事"}, {"probability": {"variance": 2e-06, "average": 0.998091, "min": 0.995812}, "location": {"width": 169, "top": 960, "height": 28, "left": 133}, "words": "件比使用肝素少"}, {"probability": {"variance": 1e-06, "average": 0.998791, "min": 0.996107}, "location": {"width": 181, "top": 993, "height": 31, "left": 142}, "words": "【药物相互作用】"}, {"probability": {"variance": 2e-06, "average": 0.99851, "min": 0.993846}, "location": {"width": 853, "top": 1023, "height": 38, "left": 182}, "words": "在静脉注射完肝素30分钟后或皮下注射完低分子量肝素8小时后可使用比伐芦定"}, {"probability": {"variance": 0.000228, "average": 0.995852, "min": 0.907224}, "location": {"width": 912, "top": 1059, "height": 37, "left": 134}, "words": "进行了比伐芦定与血小板抑制剂如阿司匹林、噻氯匹定、氯吡格雷、阿昔单抗、埃替非"}, {"probability": {"variance": 5e-06, "average": 0.99887, "min": 0.989653}, "location": {"width": 892, "top": 1094, "height": 39, "left": 136}, "words": "巴肽或替罗非班的相互作用研究,结果显示,上述联合用药没有药效学上的相互作用"}, {"probability": {"variance": 0.003891, "average": 0.976493, "min": 0.73613}, "location": {"width": 865, "top": 1129, "height": 41, "left": 184}, "words": "从药物作用机理可知,比伐芦定与抗凝药物(肝素、华法林血小板球蛋白或血小"}, {"probability": {"variance": 2e-06, "average": 0.998965, "min": 0.99133}, "location": {"width": 913, "top": 1167, "height": 39, "left": 136}, "words": "板抑制剂)联合用药可能会增加出血的危险,在任何情况下,当比伐芦定与血小板抑制"}, {"probability": {"variance": 1.8e-05, "average": 0.998415, "min": 0.977098}, "location": {"width": 679, "top": 1204, "height": 38, "left": 134}, "words": "剂或抗凝药物联合用药时,要经常监测临床和生物学的凝血参数"}, {"probability": {"variance": 1e-06, "average": 0.998579, "min": 0.997092}, "location": {"width": 131, "top": 1247, "height": 28, "left": 144}, "words": "【药物过量】"}, {"probability": {"variance": 0.000146, "average": 0.996215, "min": 0.924484}, "location": {"width": 865, "top": 1273, "height": 40, "left": 185}, "words": "单次静推超过7.5mg/ml剂量没有发现出血或其他不良反应,停止使用比伐芦定后"}, {"probability": {"variance": 0, "average": 0.99935, "min": 0.997083}, "location": {"width": 900, "top": 1308, "height": 40, "left": 138}, "words": "由于代谢的作用,体内抗凝血作用会逐渐降低。使用过量时,应立刻停止使用比伐芦定"}, {"probability": {"variance": 7e-06, "average": 0.998545, "min": 0.984885}, "location": {"width": 910, "top": 1344, "height": 40, "left": 139}, "words": "并密切观察患者有无出血征兆。比伐芦定可以通过血液透析清除(见药代动力学),目"}, {"probability": {"variance": 2e-06, "average": 0.998793, "min": 0.993967}, "location": {"width": 341, "top": 1386, "height": 34, "left": 139}, "words": "前还没有发现比伐芦定的解毒药"}, {"probability": {"variance": 1e-06, "average": 0.999122, "min": 0.997892}, "location": {"width": 131, "top": 1424, "height": 28, "left": 147}, "words": "【药理毒理】"}, {"probability": {"variance": 3e-06, "average": 0.998715, "min": 0.992478}, "location": {"width": 863, "top": 1450, "height": 41, "left": 187}, "words": "比伐芦定是凝血酶的直接抑制剂,与游离及血栓上凝血酶的催化位点和阴离子外结"}, {"probability": {"variance": 5e-06, "average": 0.99887, "min": 0.987585}, "location": {"width": 911, "top": 1486, "height": 41, "left": 140}, "words": "合位点特异结合起抑制作用。凝血酶是一种丝氨酸蛋白酶,在血栓形成过程中起重要的"}, {"probability": {"variance": 0.010613, "average": 0.959851, "min": 0.544036}, "location": {"width": 900, "top": 1523, "height": 38, "left": 141}, "words": "作用,它首先将纤维蛋白原分解为纤维蛋白单体,然后将凝血酶因子XII激活为XIla"}, {"probability": {"variance": 2.2e-05, "average": 0.998293, "min": 0.971858}, "location": {"width": 911, "top": 1558, "height": 40, "left": 141}, "words": "使纤维蛋白之间共价连接成为稳定的网架,形成血栓。凝血酶同时还可激活凝血酶因子"}], "language": 3}